Inflazome Receives Funding from The Michael J. Fox Foundation for Parkinson’s Research
Funding in excess of US$1 million to support the development of a brain imaging probe for patient diagnosis and the
Eisai, Biogen kick-off phase 3 testing early Alzheimer’s disease antibody, amid dropping aducanunab trial. Eisai’s US company presents AD pipeline
Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.
Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
Application supported by the Phase 3 MAIA study for daratumumab in combination with lenalidomide and dexamethasone for the treatment of
Advicenne Reports Full Year 2018 Financial Results and Confirms Operational Outlook for 2019
NÎMES, France–(BUSINESS WIRE)–Regulatory News: Advicenne (Paris:ADVIC) (Euronext: ADVIC – FR0013296746), a pharmaceutical company specializing in the development of adult and pediatric
Abzena Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line Development
CAMBRIDGE, England–(BUSINESS WIRE)–Abzena, the leading biologics target to GMP partner research organisation (PRO), announced its Cambridge UK site has brought
Rare Diseases: PKU GOLIKE® Debuts in Germany
BALERNA, Switzerland–(BUSINESS WIRE)–PKU GOLIKE®, the brand new generation of Phenylalanine (PHe)-free medical food for Phenylketonuria (PKU) dietary management, is now
Modra Pharmaceuticals Announces First Patients Treated in Phase IIa Metastatic Breast Cancer Trial
–Study will test efficacy and safety of novel docetaxel-based oral therapeutic– AMSTERDAM–(BUSINESS WIRE)–Modra Pharmaceuticals B.V. (“Modra”) today announced that the
Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis
OSS, The Netherlands–(BUSINESS WIRE)–Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of immunological and oncological indications, today
Alvogen’s Taiwan company – Lotus – exchange stake with Fuji Pharma
@alvogenpr subsidiary in Taiwan, Lotus Pharmaceuticals today announced capital and business collaboration agreements with Fuji Pharma in Japan, as Fuji has acquired a 2.0% stake in Lotus for approximately US$20 million (or NT$ 617 million, JPY 2.2 billion). Lotus has also acquired 3.9% stake in Fuji for an equal sum.
Verona Pharma welcomes Non-Executive Director
Verona Pharma as Non-Executive Director